title: [Neoadjuvant chemoradiotherapy for locally advanced rectal cancer].
abstract: A total of 37 patients treated with chemoradiotherapy between 2008 and 2011 were analyzed. Radiotherapy was administered in fractions of 1.8 Gy/day for 25 days. S-1 was administered orally in a fixed daily dose of 80 mg/m2 on days 1-5, 8-12, 22-26, and 29-33. Irinotecan(CPT-11 80 mg/m2) was infused on days 1, 8, 22, and 29. Curative surgery was performed 6-8 weeks later. The clinical downstaging rate was 40%. During the median follow-up time of 664 days, 37 patients survived. Recurrence was found in 8 patients. Local recurrence (pelvic lymph node metastasis) was only observed in 1 patient. Grade 3-4 toxic effects, including interstitial pneumonia, occurred in 27% of the patients. Neoadjuvant chemoradiotherapy may result in excellent local control with acceptable morbidity. However, longer follow up is required to assess neoadjuvant chemoradiotherapy for locally advanced rectal cancers.
authors.affiliation: Dept. of Surgery, Kyoto Prefectural University of Medicine, Japan.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kuriu
authors.forename: Yukihito
authors.initials: Y
authors.lastname: Kokuba
authors.forename: Yasutoshi
authors.initials: Y
authors.lastname: Murayama
authors.forename: Shuhei
authors.initials: S
authors.lastname: Komatsu
authors.forename: Atsushi
authors.initials: A
authors.lastname: Shiozaki
authors.forename: Hisashi
authors.initials: H
authors.lastname: Ikoma
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Nakanishi
authors.forename: Daisuke
authors.initials: D
authors.lastname: Ichikawa
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Fujiwara
authors.forename: Kazuma
authors.initials: K
authors.lastname: Okamoto
authors.forename: Toshiya
authors.initials: T
authors.lastname: Ochiai
authors.forename: Eigo
authors.initials: E
authors.lastname: Otsuji
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D059248:Chemoradiotherapy; D004338:Drug Combinations; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D012004:Rectal Neoplasms / Q000473:pathology / Q000628:therapy*; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002166:Camptothecin